Acnezine solution has been scientifically tested and is proven to give you 100% results. Adolescents, adults and everyone irrespective of their age can use this acne treatment product. It can safely be used to cure facial acne or acne in any other part of the body. Acne can be used on pimples, blackheads, whiteheads and it effectively reduces spots and redness of the acne prone skin. It completely dries the acne and leaves no trace of it. The best bet is that the formulation is completely free from side effects.
Recommended by Top Dermatologists
Impurities and imbalances within the body give rise to acne. The skin should be kept oil and dirt free to get rid of acne. It is therefore that this acne treatment product works by cleansing the acne prone area. It acts skin deep and helps to cure acne from within the skin. Acnezine is rich in anti-oxidants, which capture the harmful free radicals from deep inside the skin. Its anti-oxidant property also helps in treating ageing and skin blemishes. Acnezine also helps to relax the otherwise inflamed and irritated skin and speeds up the healing process.
Acnezine is a wonder drug and is known to have given satisfactory results to all the people who have tried it. Acne can bring in a lot of discomfort in the lives of people. Acnezine not only combats acne problems but also brings back the confidence on your face. If you have tried almost everything under the sun to get rid of acne and with vain, then you will be surprised at the easiness with which Acnezine works. And you get all this without any known side effect as this acne treatment product is completely natural!
Source: http://www.msokorea.com/acne/0,6600,385780,00.html
Tuesday, May 19, 2009
Tuesday, May 12, 2009
Botox Maker Allergan Faces Nestle-L’Oreal Challenge in Europe
Botox faces its greatest challenge in the market to wipe the wrinkles off European foreheads when a Nestle SA-L’Oreal SA joint venture starts selling its own injectable skin treatment next month.
Azzalure, as the new product is known, will go on sale in the U.K. in “coming days,” said Francois Fournier, who heads L’Oreal and Nestle’s Galderma venture in Europe. France will follow, and Galderma aims to sell the treatment in all of Europe’s main markets by the end of 2009, he said in an interview at his Lausanne, Switzerland office last week.
Botox, made by Allergan Inc. from a purified form of a deadly poison, has had few challengers since the 1990s, when doctors started using it to treat wrinkles. Sales last year were $1.3 billion, and the drug controlled 83 percent of the global market for neurotoxins that paralyze certain muscles or nerves, aiming to give patients a more youthful appearance.
Ipsen SA, the French drugmaker that granted Galderma the distribution rights for Azzalure, wants a piece of the action, and on April 30 got approval for sale of the treatment in the U.S. under the brand Dysport.
Competition in the U.S. and Europe “combined is going to put a dent in Allergan’s market share,” said Peter Bye, an analyst at Jefferies Group Inc. with a “hold” rating on the U.S. company’s stock. Azzalure is “a bit more of a threat.” He said Botox may lose 4 percentage points of market share in 2009.
L’Oreal, the world’s biggest cosmetics maker, teamed up with Nestle, one of its biggest shareholders, to create Galderma as a prescription skin-treatment business in 1981. The world’s biggest food company has said Galderma joined Hot Pockets sandwiches and Buitoni pasta among 29 Nestle brands with revenue exceeding 1 billion Swiss francs ($880 million) last year.
Full Story: http://www.bloomberg.com/apps/news?pid=20601100&sid=aoETYzMjS.Zc&refer=germany
Azzalure, as the new product is known, will go on sale in the U.K. in “coming days,” said Francois Fournier, who heads L’Oreal and Nestle’s Galderma venture in Europe. France will follow, and Galderma aims to sell the treatment in all of Europe’s main markets by the end of 2009, he said in an interview at his Lausanne, Switzerland office last week.
Botox, made by Allergan Inc. from a purified form of a deadly poison, has had few challengers since the 1990s, when doctors started using it to treat wrinkles. Sales last year were $1.3 billion, and the drug controlled 83 percent of the global market for neurotoxins that paralyze certain muscles or nerves, aiming to give patients a more youthful appearance.
Ipsen SA, the French drugmaker that granted Galderma the distribution rights for Azzalure, wants a piece of the action, and on April 30 got approval for sale of the treatment in the U.S. under the brand Dysport.
Competition in the U.S. and Europe “combined is going to put a dent in Allergan’s market share,” said Peter Bye, an analyst at Jefferies Group Inc. with a “hold” rating on the U.S. company’s stock. Azzalure is “a bit more of a threat.” He said Botox may lose 4 percentage points of market share in 2009.
L’Oreal, the world’s biggest cosmetics maker, teamed up with Nestle, one of its biggest shareholders, to create Galderma as a prescription skin-treatment business in 1981. The world’s biggest food company has said Galderma joined Hot Pockets sandwiches and Buitoni pasta among 29 Nestle brands with revenue exceeding 1 billion Swiss francs ($880 million) last year.
Full Story: http://www.bloomberg.com/apps/news?pid=20601100&sid=aoETYzMjS.Zc&refer=germany
Monday, May 4, 2009
New generics
Zydus announced that it has received final FDA approval for its Abbreviated New Drug Application (ANDA) for Topiramate Tablets USP, 25 mg, 50 mg, 100 mg, and 200 mg. Topiramate tablets are the generic version of Ortho-McNeil-Janssen's Topamax Tablets.
Ranbaxy announced the FDA has approved its ANDA to market and manufacture Ramipril Capsules 5 mg and 10 mg. The FDA had determined the Ranbaxy formulations to be bioequivalent and as having the same therapeutic effect as that of the reference-listed drug, Altace, by King.
Teva announced the FDA granted final approval of its ANDA to market Minocycline HCl Capsules, its generic version of Medicis' acne treatment Solodyn Extended-Release Tablets, 45 mg, 90 mg, and 135 mg.
Ranbaxy announced that it has received an approval from the FDA for its ANDA for Quinapril + HCTZ Tablets (quinapril hydrochloride and hydrochlorothiazide), 10 mg/12.5 mg, 20 mg/12.5 mg, and 20mg/25mg. The FDA determined the Ranbaxy formulations to be bioequivalent and as having the same therapeutic effect as that of the reference-listed drug, Pfizer's Accuretic Tablets.
Full Coverage: http://www.modernmedicine.com/modernmedicine/Over+the+Counter/New-products-Rx-generic-OTC-May-2009/ArticleStandard/Article/detail/596058?contextCategoryId=40159
Ranbaxy announced the FDA has approved its ANDA to market and manufacture Ramipril Capsules 5 mg and 10 mg. The FDA had determined the Ranbaxy formulations to be bioequivalent and as having the same therapeutic effect as that of the reference-listed drug, Altace, by King.
Teva announced the FDA granted final approval of its ANDA to market Minocycline HCl Capsules, its generic version of Medicis' acne treatment Solodyn Extended-Release Tablets, 45 mg, 90 mg, and 135 mg.
Ranbaxy announced that it has received an approval from the FDA for its ANDA for Quinapril + HCTZ Tablets (quinapril hydrochloride and hydrochlorothiazide), 10 mg/12.5 mg, 20 mg/12.5 mg, and 20mg/25mg. The FDA determined the Ranbaxy formulations to be bioequivalent and as having the same therapeutic effect as that of the reference-listed drug, Pfizer's Accuretic Tablets.
Full Coverage: http://www.modernmedicine.com/modernmedicine/Over+the+Counter/New-products-Rx-generic-OTC-May-2009/ArticleStandard/Article/detail/596058?contextCategoryId=40159
Tuesday, April 28, 2009
Don't let the bed bugs bite
VERY few people are aware that there seems to be a worldwide epidemic of bed bugs. The statistics are there to prove this. The bed bug can live for months without feeding and they can hide themselves in clothes or luggage. So a guest at a hotel may bring them into a hotel in his clothes or in his luggage and the bed bug will then infest the hotel room. The bed bug may have come from an infested home or from another infested hotel.
 |
Usually we go to bed at night and when we wake up we notice the bite marks from the bed bug on the skin and blood on our clothes or on the sheets. Some people may have an urticarial (rash) reaction in the morning from the bites of the bed bug.
Now bed bugs as far as we know do not transmit any diseases but they have tested positive for the virus Hepatitis B and have been suspected to be transmitters of this disease. The bite of the bed bug is painless but the saliva causes the problems.
The bed bug is a small bug that is black in colour and it has two rudimentary wings and six legs. It lives in the crevices of our beds and in our mattresses.
The treatment of bed bug bites is simply one per cent hydrocortisone cream for kids and Betnovate for adults. For the itching we may use oral antihistamines like DPH or Histal.
Tuesday, April 21, 2009
GSK acquires leading skincare specialist
Under the terms of the agreement GSK will acquire the total share capital of Stiefel for $2.9 billion. GSK also expects to assume $400 million of net debt upon closing. A further $300 million cash payment will be made depending on future performance.
GSK's existing prescription dermatological products will be combined with Stiefel's and the new specialist global business will operate under the Stiefel identity within the GSK Group.
The new business will have a broad portfolio of dermatology products including Stiefel's leading brands: Duac, for acne, Olux E for dermatitis and Soriatane for the treatment of severe psoriasis. GSK's key dermatology brands include: Bactroban, Cutivate and the recently launched Altabax.
Stiefel, part-owned by buyout firm Blackstone Group, is the world's largest independent dermatology company, with a range of prescription and over-the-counter products. According to Reuters.com it was put up for sale a month ago and attracted interest from a number of large pharmaceutical companies, including Novartis and Johnson & Johnson.
Following the announcement, GSK Chief Executive Andrew Witty said: "As part of our strategy to grow and diversify GSK's business, we are continuing to make new investments through targeted acquisitions. This transaction will create a new world-leading, specialist dermatology business and re-energize our existing dermatology products.
"The addition of Stiefel's broad portfolio will provide immediate new revenue flows to GSK with significant opportunities to enhance growth through leveraging our existing global commercial infrastructure and manufacturing capability. We look forward to working with Stiefel to develop this exciting opportunity."
complete coverage: http://edition.cnn.com/2009/BUSINESS/04/20/gsk.stiefel.sale/
GSK's existing prescription dermatological products will be combined with Stiefel's and the new specialist global business will operate under the Stiefel identity within the GSK Group.
The new business will have a broad portfolio of dermatology products including Stiefel's leading brands: Duac, for acne, Olux E for dermatitis and Soriatane for the treatment of severe psoriasis. GSK's key dermatology brands include: Bactroban, Cutivate and the recently launched Altabax.
Stiefel, part-owned by buyout firm Blackstone Group, is the world's largest independent dermatology company, with a range of prescription and over-the-counter products. According to Reuters.com it was put up for sale a month ago and attracted interest from a number of large pharmaceutical companies, including Novartis and Johnson & Johnson.
Following the announcement, GSK Chief Executive Andrew Witty said: "As part of our strategy to grow and diversify GSK's business, we are continuing to make new investments through targeted acquisitions. This transaction will create a new world-leading, specialist dermatology business and re-energize our existing dermatology products.
"The addition of Stiefel's broad portfolio will provide immediate new revenue flows to GSK with significant opportunities to enhance growth through leveraging our existing global commercial infrastructure and manufacturing capability. We look forward to working with Stiefel to develop this exciting opportunity."
complete coverage: http://edition.cnn.com/2009/BUSINESS/04/20/gsk.stiefel.sale/
Tuesday, April 14, 2009
Azelaic acid key to plant immunity
A common plant metabolite used in creams for acne treatment and rosacea has a major role in priming plants’ systemic immune system, US researchers have found.
Azelaic acid has antibacterial and anti-inflammatory properties and is commonly used in dermatological applications in humans.
Now, it has been identified as a signalling weapon in Arabidopsis to prime the plants to accumulate salicylic acid upon infection.
Salicylic acid, which is also used popularly in skin treatments, is a phytohormone in plants which plays a role in pathogen resistance. It is highly active in systemic acquired resistance (SAR) in plants, in which resistance to localised infections develops as a means of mounting a stronger defense upon secondary infection.
SAR involves infected leaves developing a sap called petiole exudate, which is then sent through the vascular system to confer resistance to uninfected leaves.
The US team, led by Ho Won Jung and Jean Greenberg from the University of Chicago, used gas chromatography and mass spectrometry to look for metabolites that were highly active in SAR-induced exudates.
Source: http://www.biotechnews.com.au/article/298428/azelaic_acid_key_plant_immunity
Azelaic acid has antibacterial and anti-inflammatory properties and is commonly used in dermatological applications in humans.
Now, it has been identified as a signalling weapon in Arabidopsis to prime the plants to accumulate salicylic acid upon infection.
Salicylic acid, which is also used popularly in skin treatments, is a phytohormone in plants which plays a role in pathogen resistance. It is highly active in systemic acquired resistance (SAR) in plants, in which resistance to localised infections develops as a means of mounting a stronger defense upon secondary infection.
SAR involves infected leaves developing a sap called petiole exudate, which is then sent through the vascular system to confer resistance to uninfected leaves.
The US team, led by Ho Won Jung and Jean Greenberg from the University of Chicago, used gas chromatography and mass spectrometry to look for metabolites that were highly active in SAR-induced exudates.
Source: http://www.biotechnews.com.au/article/298428/azelaic_acid_key_plant_immunity
Tuesday, April 7, 2009
Getting under the skin of treatments
IT IS impossible to open a magazine these days without seeing an advert or article on some kind of cosmetic enhancement.
They will usually feature an impossibly glamorous model who is at least 15 years away from needing any kind of cosmetic intervention.
A huge variety of treatments are available, from creams, which reduce your wrinkles, to plastic surgery under general anaesthetic.
All make bold promises about how much better they will make you look and feel. But interestingly they seldom, if ever, offer you your money back if the procedure fails.
Having said that, there are effective techniques available, but how do you know which ones are safe and effective and which will have been abandoned in a few years due to lack of efficacy or some high-profile disasters?
In this article I would like to outline some of the effective treatments available in the field of cosmetic dermatology and give you some guidance about which cosmetic procedure may be right for you.
Firstly, you should begin by looking in the mirror. Everyone would like to change something about their appearance but the important thing to bear in mind is whether the change will really be worthwhile and give you a lasting benefit, or whether it will be something that nobody would notice.
Source: http://www.walesonline.co.uk/news/health-news/2009/04/06/getting-under-the-skin-of-treatments-91466-23319404/
They will usually feature an impossibly glamorous model who is at least 15 years away from needing any kind of cosmetic intervention.
A huge variety of treatments are available, from creams, which reduce your wrinkles, to plastic surgery under general anaesthetic.
All make bold promises about how much better they will make you look and feel. But interestingly they seldom, if ever, offer you your money back if the procedure fails.
Having said that, there are effective techniques available, but how do you know which ones are safe and effective and which will have been abandoned in a few years due to lack of efficacy or some high-profile disasters?
In this article I would like to outline some of the effective treatments available in the field of cosmetic dermatology and give you some guidance about which cosmetic procedure may be right for you.
Firstly, you should begin by looking in the mirror. Everyone would like to change something about their appearance but the important thing to bear in mind is whether the change will really be worthwhile and give you a lasting benefit, or whether it will be something that nobody would notice.
Source: http://www.walesonline.co.uk/news/health-news/2009/04/06/getting-under-the-skin-of-treatments-91466-23319404/
Subscribe to:
Posts (Atom)
